Polaryx Therapeutics is a founder-controlled rare-disease company that listed on Nasdaq without raising primary capital and still has not dosed a Phase 2 patient. The equity is a call on whether a reformulated oral version of gemfibrozil can show activity across four ultra-rare pediatric lysosomal storage disorders before the cash runs out. A May private placement of ten million at about four a share bought calendar, not proof. The tape has since cut that raise almost in half.
The tension is structural rather than cyclical. Management still carries a going-concern warning, the first chief medical officer left in mid-July, and the replacement arrived only in September, weeks before a planned fourth-quarter start of the SOTERIA basket study. Mid-year cash sat just above eleven million against a market value near one hundred million, which means almost the entire capitalization is option value on a trial that has a protocol and a contract research organization but no enrolled children. Related-party control around Mstone, the vehicle tied to chairman and chief executive Alex Yang, sits near half the vote, so any partnership or sale conversation runs through one desk.
The next several months resolve a simple sequence. Either first patients enter SOTERIA on the stated fourth-quarter clock and the open-label cohorts begin to generate something a regulator can read against natural history, or the company returns to the equity market at a price well below the May raise while the going-concern language is still on the page. Does the basket start before the next dilution, and does anyone outside the controlling stockholder treat that start as more than a listing narrative?